| |   | | | | By Ed Silverman Mike Reddy for STAT Voluntary licensing holds some promise for improving drug access in low- and middle-income countries, but hurdles remain. Read More | | By Ed Silverman Melissa Brower/Centers for Disease Control and Prevention via AP The fund invested $7.5 million in BioVersys, which is developing an antibiotic to combat a type of bacteria that affects hospitalized patients. Read More | | By Allison DeAngelis Ruby Wallau for STAT Priya Singhal, who has served as interim R&D chief since November 2021, will serve as the new head of development at Biogen. Read More | | Sponsored Insight by BIOTECH SHOWCASE™ Discover cutting-edge technologies and the latest innovations at Biotech Showcase Biotech Showcase, taking place January 9-11, 2023, will feature 400 presenting companies. Ranging from publicly traded companies to seed-stage biotechs, presenting companies will showcase the latest innovations available for investment and licensing opportunities. Take advantage of this opportunity to meet one-to-one with the most innovative companies in the biopharma sector. Don't delay! There is still time to register. Secure your spot today. | | By Rachel Cohrs Christine Kao/STAT The legislative saga on drug pricing is mostly over for now, but drug pricing policy will still offer plenty of controversy in 2023. Read More | | By Damian Garde and Meg Tirrell and Adam Feuerstein We delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's. Read More | |
No comments